LENZ Therapeutics (LENZ) Insider Thunen Buys 22,100 Shares
Shelley Thunen acquired 22,100 shares of LENZ on June 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Shelley Thunen bought 22,100 shares of LENZ Therapeutics, Inc. ($LENZ) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LENZ is down 12.2% after 1 week, down 24.7% after 1 month and down 50.7% to date (from the $6.63 close on Jun 15, 2026).
LENZ
LENZ Therapeutics, Inc.
Key Points
- Shelley Thunen bought 22,100 shares of LENZ on June 15, 2026, as the stock trades at $6.77.
- LENZ has seen varied institutional activity, with Versant Venture Management doubling its stake by adding 2.66 million shares.
- Analysts from Citigroup and HC Wainwright & Co. maintain a 'buy' rating, with price targets up to $38.
Get $LENZ trade alerts by text
We text you when insiders, Congress or big funds trade $LENZ. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated LENZ Therapeutics, Inc. alert may contain errors. Disclosures
Shelley Thunen, an insider at LENZ, purchased 22,100 shares of the company on June 15, 2026. The stock is currently trading at $6.77. This transaction is not part of a pre-planned trading program.
Other Institutional Activity in LENZ
LENZ has been the focus of various institutional investors. Versant Venture Management, LLC significantly increased its position by adding 2,656,888 shares, bringing its total to 5,313,776 shares valued at approximately $48.6 million. Meanwhile, RA Capital Management, L.P. maintained its stake at 4,178,823 shares, worth about $38.2 million. Alpha Wave Global, LP also kept its holdings unchanged at 3,612,211 shares, valued at $33.1 million. FMR LLC slightly reduced its position by 104,934 shares, resulting in a total of 3,597,784 shares worth $32.9 million. BlackRock, Inc. increased its holdings by 284,817 shares, reaching a total of 1,976,823 shares valued at $18.1 million.
Insider Buying and Selling at LENZ Therapeutics, Inc.
On June 15, 2026, several insiders at LENZ made similar purchases. Zachary Scheiner, Frederic Guerard, James McCollum, Shelley Thunen, Kimberlee Drapkin, and Jeffrey George each acquired 22,100 shares. These transactions were not part of pre-planned trading programs.
Analysts Set New Price Targets
Analyst firms have been active in updating their perspectives on LENZ. On May 13, 2026, Citigroup maintained its 'buy' rating with a $20 price target. HC Wainwright & Co. also held its 'buy' rating with a $38 target on May 12, 2026. However, Piper Sandler downgraded the stock to 'hold' and set a $12 target on the same day. Overall, the consensus remains positive, with a 'buy' recommendation and an average price target reflecting optimism among analysts.
Bottom Line
Shelley Thunen's recent purchase of LENZ shares adds to a series of insider transactions, reflecting some confidence in the company's prospects. Institutional investors have shown mixed actions, with some increasing their stakes significantly. Analysts continue to view LENZ favorably, maintaining high price targets. As always, it's important to remember that insider transactions and analyst ratings are just pieces of the broader investment puzzle.
Related Filing Alerts
Source: Shelley Thunen's Form 4 filing on $LENZ (Jun 15, 2026). Find the original filing: LENZ Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts